Drugs / LEO 29102
last change Mar 2013 re-read 2 minutes ago

LEO 29102

Developed for
atopic eczema · psoriasis
Investigated by
LEO Pharma

Trials 7 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 15 trials
Phase 1 NCT01466478 Nov → Dec 2011 psoriasis LEO Pharma Completed No outcome recorded
Phase 1 NCT01447758 Sep 2011 → Mar 2013 atopic eczema LEO Pharma Terminated No outcome recorded
Phase 1 NCT01423656 Aug 2011 → Nov 2012 atopic eczema LEO Pharma Completed No outcome recorded
Phase 1 NCT00958516 Sep → Oct 2009 atopic eczema LEO Pharma Completed No outcome recorded
Phase 1 NCT00891709 Mar → Jun 2009 atopic eczema LEO Pharma Completed No outcome recorded
Phase 22 trials
Phase 2 NCT01037881 Dec 2009 → Jun 2010 atopic eczema LEO Pharma Completed No outcome recorded
Phase 2 NCT00875277 Apr → May 2009 psoriasis LEO Pharma Completed No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT01005823 Comparator Oct 2009 → May 2010 atopic eczema LEO Pharma Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 8 sources stand behind the page.

FieldValueCited text
Known as LEO 29102 ClinicalTrials.gov intervention name — accepted as the source's own label NCT01423656
7

NCT00958516

NCT00891709

NCT01037881

NCT00875277

NCT01005823

NCT01447758

NCT01466478

Route Other “LEO 29102 is administered cutaneously as single and multiple doses” NCT00891709